PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Apitegromab→

Apitegromab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2278276-46-1
Molecular formula
C6412H9866N1710O2026S44
Molecular weight
144736.04 g/mol
Drug class
Fully human monoclonal IgG4 antibodymyostatin-pathway inhibitor
Mechanism of action
Binds promyostatin and latent myostatin and inhibits activation of myostatin, blocking myostatin signalling involved in limiting skeletal-muscle growth.
Indications / reported uses
  • Treatment of spinal muscular atrophy (SMA) in adults and paediatric patients aged 2 years and older who are currently receiving an SMN2-targeted treatment under the US FDA Isembyld indication (approval 11 Sep 2026)

Sources: US FDA — Isembyld approval · FDA Purple Book — Isembyld product details · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Apitegromab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Apitegromab Permitted Daily Exposure (PDE) report (the Apitegromab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Apitegromab Occupational Exposure Limit (OEL) report (the Apitegromab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.